ERYTECH PHARMA - SPON ADR (ERYP) Stock Price, Forecast & Analysis
USA - NASDAQ:ERYP - US29604W1080 - ADR
ERYP Key Statistics, Chart & Performance
The current stock price of ERYP is 0.78 USD. In the past month the price decreased by -9.52%. In the past year, price decreased by -30.36%.
ERYP Latest News, Press Relases and Analysis
ERYP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About ERYP
Company Profile
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Company Info
ERYTECH PHARMA - SPON ADR
60 avenue Rockefeller, Batiment Adenine
Lyon AUVERGNE-RHONE-ALPES 69008 FR
CEO: Gil Beyen
Employees: 49
Phone: 33478744438.0
ERYTECH PHARMA - SPON ADR / ERYP FAQ
What does ERYTECH PHARMA - SPON ADR do?
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Can you provide the latest stock price for ERYTECH PHARMA - SPON ADR?
The current stock price of ERYP is 0.78 USD.
What is the dividend status of ERYTECH PHARMA - SPON ADR?
ERYP does not pay a dividend.
What is the ChartMill rating of ERYTECH PHARMA - SPON ADR stock?
ERYP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of ERYTECH PHARMA - SPON ADR (ERYP) based on its PE ratio?
ERYTECH PHARMA - SPON ADR (ERYP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.55).
Can you provide the upcoming dividend date for ERYTECH PHARMA - SPON ADR?
The next ex-dividend date for ERYTECH PHARMA - SPON ADR (ERYP) is May 16, 2022.
ERYP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ERYP. When comparing the yearly performance of all stocks, ERYP is a bad performer in the overall market: 86.71% of all stocks are doing better.
ERYP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERYP. While ERYP seems to be doing ok healthwise, there are quite some concerns on its profitability.
ERYP Financial Highlights
Over the last trailing twelve months ERYP reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 99.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.44 |
ERYP Forecast & Estimates
9 analysts have analysed ERYP and the average price target is 3.94 USD. This implies a price increase of 405.11% is expected in the next year compared to the current price of 0.78.
For the next year, analysts expect an EPS growth of 22.35% and a revenue growth 16.44% for ERYP